The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.
Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...
Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...
The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...
Artificial Intelligence (AI) can play a crucial role in drug discovery, but the lack of sufficient data in this area remains ...
Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...
The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback